Manages manifestations of psychotic disorders. ANDA 212996, held by Lannett Co Inc. Chlorpromazine Hydrochloride.
As of Nov 16, 2026, ANDA 212996 (Chlorpromazine Hydrochloride), held by Lannett Co Inc, was first approved by FDA on Jan 22, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 22, 2021 | Original application | Approved | None posted |
| Chlorpromazine Hydrochloride10MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride25MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride50MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride100MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride200MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters